Rare disease: industry, patients and tech join forces on diagnosisTakeda’s Adam Zaeske discusses how cross-sector collaboration is shaping a brighter future for rare disease diagnosis. Diagnosis can Share XRare disease: industry, patients and tech join forces on diagnosishttps://pharmaphorum.com/views-and-analysis/rare-disease-industry-patients-and-tech-join-forces-on-the-diagnostic-odyssey/
After Sanofi’s setbacks, Takeda eyes finish line with its dengue vaccineTakeda has revealed long-term clinical trial results with its dengue vaccine that reinforce its safety and efficacy – Share XAfter Sanofi’s setbacks, Takeda eyes finish line with its dengue vaccinehttps://pharmaphorum.com/news/after-sanofis-setbacks-takeda-eyes-finish-line-with-its-dengue-vaccine/
Takeda buys Maverick as T-Cell engager research hots upTakeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer Share XTakeda buys Maverick as T-Cell engager research hots uphttps://pharmaphorum.com/news/takeda-buys-maverick-as-t-cell-engager-research-hots-up/
Switch data back Chiesi/Protalix long-acting Fabry drugChiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, Share XSwitch data back Chiesi/Protalix long-acting Fabry drughttps://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/
Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
J&J’s Darzalex Faspro is first US therapy for rare blood disorderJohnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain Share XJ&J’s Darzalex Faspro is first US therapy for rare blood disorderhttps://pharmaphorum.com/news/jjs-darzalex-faspro-is-first-us-therapy-for-rare-blood-disorder/
Pandemic has little impact on pharma’s reputation, says reportThe pandemic has had very little positive impact on the public’s perceptions of pharma although the industry has Share XPandemic has little impact on pharma’s reputation, says reporthttps://pharmaphorum.com/news/pandemic-has-little-impact-on-pharmas-reputation-says-report/
Takeda to partner on patient-centric data with SeqsterTakeda has partnered with patient data firm Seqster in a drive to improve care through better access and Share XTakeda to partner on patient-centric data with Seqsterhttps://pharmaphorum.com/news/takeda-to-partner-on-patient-centric-data-with-seqster/
Takeda’s bleeding disorder drug Veyvondi backed for NHS useNHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it Share XTakeda’s bleeding disorder drug Veyvondi backed for NHS usehttps://pharmaphorum.com/news/takedas-bleeding-disorder-drug-veyvondi-backed-for-nhs-use/
